212 related articles for article (PubMed ID: 35853675)
1. Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST.
Braun J; Kiltz U; Deodhar A; Tomita T; Dougados M; Bolce R; Sandoval D; Lin CY; Walsh J
RMD Open; 2022 Jul; 8(2):. PubMed ID: 35853675
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
Dougados M; Wei JC; Landewé R; Sieper J; Baraliakos X; Van den Bosch F; Maksymowych WP; Ermann J; Walsh JA; Tomita T; Deodhar A; van der Heijde D; Li X; Zhao F; Bertram CC; Gallo G; Carlier H; Gensler LS;
Ann Rheum Dis; 2020 Feb; 79(2):176-185. PubMed ID: 31685553
[TBL] [Abstract][Full Text] [Related]
3. Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials.
van der Horst-Bruinsma IE; de Vlam K; Walsh JA; Bolce R; Hunter T; Sandoval D; Zhu D; Geneus V; Soriano ER; Magrey M
Adv Ther; 2022 Jun; 39(6):2806-2819. PubMed ID: 35429281
[TBL] [Abstract][Full Text] [Related]
4. Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results.
Deodhar AA; Mease PJ; Rahman P; Navarro-Compán V; Strand V; Hunter T; Bolce R; Leon L; Lauzon S; Marzo-Ortega H
BMC Rheumatol; 2021 Sep; 5(1):35. PubMed ID: 34538257
[TBL] [Abstract][Full Text] [Related]
5. Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y).
Landewé RB; Gensler LS; Poddubnyy D; Rahman P; Hojnik M; Li X; Liu Leage S; Adams D; Carlier H; Van den Bosch F;
Ann Rheum Dis; 2021 Aug; 80(8):1022-1030. PubMed ID: 33958326
[TBL] [Abstract][Full Text] [Related]
6. Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies.
Kiltz U; Wei JC; van der Heijde D; van den Bosch F; Walsh JA; Boonen A; Gensler LS; Hunter T; Carlier H; Dong Y; Li X; Bolce R; Strand V; Braun J
J Rheumatol; 2021 Feb; 48(2):188-197. PubMed ID: 32669450
[TBL] [Abstract][Full Text] [Related]
7. Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years.
van der Heijde D; Østergaard M; Reveille JD; Baraliakos X; Kronbergs A; Sandoval DM; Li X; Carlier H; Adams DH; Maksymowych WP
J Rheumatol; 2022 Mar; 49(3):265-273. PubMed ID: 34853086
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program.
Deodhar A; Poddubnyy D; Rahman P; Ermann J; Tomita T; Bolce R; Leage SL; Kronbergs A; Johnson C; Araújo J; Leung A; van der Heijde D
J Rheumatol; 2023 Aug; 50(8):1020-1028. PubMed ID: 36792107
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
[TBL] [Abstract][Full Text] [Related]
10. Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study.
Xue Y; Hu J; Liu D; Li J; Wu H; Tan C; Dai L; Sun L; Li Z; Xiao Z; Huang C; Yan Y; Ji F; Chen R; Zou H
BioDrugs; 2024 Jan; 38(1):145-156. PubMed ID: 37737952
[TBL] [Abstract][Full Text] [Related]
11. Ixekizumab for treating ankylosing spondylitis.
Kiwalkar S; Beier S; Deodhar A
Immunotherapy; 2019 Oct; 11(15):1273-1282. PubMed ID: 31530049
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
[TBL] [Abstract][Full Text] [Related]
13. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
[TBL] [Abstract][Full Text] [Related]
14. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
van der Heijde D; Cheng-Chung Wei J; Dougados M; Mease P; Deodhar A; Maksymowych WP; Van den Bosch F; Sieper J; Tomita T; Landewé R; Zhao F; Krishnan E; Adams DH; Pangallo B; Carlier H;
Lancet; 2018 Dec; 392(10163):2441-2451. PubMed ID: 30360964
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
van der Heijde D; Deodhar A; Baraliakos X; Brown MA; Dobashi H; Dougados M; Elewaut D; Ellis AM; Fleurinck C; Gaffney K; Gensler LS; Haroon N; Magrey M; Maksymowych WP; Marten A; Massow U; Oortgiesen M; Poddubnyy D; Rudwaleit M; Shepherd-Smith J; Tomita T; Van den Bosch F; Vaux T; Xu H
Ann Rheum Dis; 2023 Apr; 82(4):515-526. PubMed ID: 36649967
[TBL] [Abstract][Full Text] [Related]
16. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
Deodhar A; van der Heijde D; Gensler LS; Kim TH; Maksymowych WP; Østergaard M; Poddubnyy D; Marzo-Ortega H; Bessette L; Tomita T; Leung A; Hojnik M; Gallo G; Li X; Adams D; Carlier H; Sieper J;
Lancet; 2020 Jan; 395(10217):53-64. PubMed ID: 31813637
[TBL] [Abstract][Full Text] [Related]
17. Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis.
Mease P; Walsh JA; Baraliakos X; Inman R; de Vlam K; Wei JC; Hunter T; Gallo G; Sandoval D; Zhao F; Dong Y; Bolce R; Marzo-Ortega H
Rheumatol Ther; 2019 Sep; 6(3):435-450. PubMed ID: 31254223
[TBL] [Abstract][Full Text] [Related]
18. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies.
Baraliakos X; Deodhar A; van der Heijde D; Magrey M; Maksymowych WP; Tomita T; Xu H; Massow U; Fleurinck C; Ellis AM; Vaux T; Shepherd-Smith J; Marten A; Gensler LS
Ann Rheum Dis; 2024 Jan; 83(2):199-213. PubMed ID: 37793792
[TBL] [Abstract][Full Text] [Related]
19. Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks.
Marzo-Ortega H; Mease PJ; Rahman P; Navarro-Compán V; Strand V; Dougados M; Combe B; Wei JC; Baraliakos X; Hunter T; Sandoval D; Li X; Zhu B; Bessette L; Deodhar A
Rheumatol Ther; 2020 Dec; 7(4):759-774. PubMed ID: 32814997
[TBL] [Abstract][Full Text] [Related]
20. The role of ixekizumab in non-radiographic axial spondyloarthritis.
San Koo B; Kim TH
Ther Adv Musculoskelet Dis; 2021; 13():1759720X20986734. PubMed ID: 33488787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
